Results 51 to 60 of about 33,935 (242)

Metabolomics Signature and Potential Application of Serum Polyunsaturated Fatty Acids Metabolism in Patients With Vitiligo

open access: yesFrontiers in Immunology, 2022
Vitiligo is a depigmented skin disorder caused by a variety of factors, including autoimmune, metabolic disturbance or their combined effect, etc.
Zhubiao Ye   +10 more
doaj   +1 more source

Common variants in FOXP1 are associated with generalized vitiligo [PDF]

open access: yes, 2010
In a recent genome-wide association study of generalized vitiligo, we identified ten confirmed susceptibility loci. By testing additional loci that showed suggestive association in the genome-wide study, using two replication cohorts of European descent,
Mauro Picardo   +87 more
core   +1 more source

The association between neural crest‐derived glia and melanocyte lineages throughout development and disease

open access: yesDevelopmental Dynamics, EarlyView.
Abstract Neural crest cells are a transient cell population that emerges from the dorsal neural tube during neurulation and migrates extensively throughout the embryo. Among their diverse derivatives, glial cells (such as Schwann and satellite ganglionic cells) and melanocytes represent two major lineages. In vitro studies suggested they share a common
Chaya Kalcheim
wiley   +1 more source

Innate immune activation in vitiligo: mechanisms and pathophysiological implications

open access: yesFrontiers in Immunology
Vitiligo is an autoimmune disease characterized by the progressive destruction of epidermal melanocytes, leading to skin depigmentation. Although significant advances have been made in understanding the pathogenesis of vitiligo, the intricate interplay ...
Yuting Wang   +5 more
doaj   +1 more source

Tolerability of Adjuvant Nivolumab in Esophageal or Gastroesophageal Junction Cancer: A Real‐World Study

open access: yesInternational Journal of Cancer, EarlyView.
ABSTRACT Adjuvant nivolumab is approved for esophageal or gastroesophageal junction cancer after neoadjuvant chemoradiotherapy and resection. In the CheckMate‐577 trial, Grade 3–5 nivolumab‐related adverse events (AEs) occurred in 5% of patients, with early discontinuation due to toxicity in 9%. However, real‐world data on immunotherapy‐related adverse
Michelle Koops van ’t Jagt   +7 more
wiley   +1 more source

Development of consensus recommendations on the management of vitiligo and the role of decapeptide in vitiligo by the delphi method

open access: yesIndian Journal of Dermatology, 2023
Background: Treatment of vitiligo is still a challenge in dermatology. Literature is sparse on the definitive clinical role of basic fibroblast growth factor (bFGF) in vitiligo patients.
Davinder Parsad   +20 more
doaj   +1 more source

Meta-Analysis of Alterations in Regulatory T Cells’ Frequency and Suppressive Capacity in Patients with Vitiligo

open access: yesJournal of Immunology Research, 2022
Vitiligo is a noncontagious autoimmune skin depigmenting disease. Regulatory T cells (Tregs) play a key role in maintaining peripheral tolerance; however, Tregs’ number, suppressive function, and associated suppressive molecules (FOXP3, IL-10, and TGF-β)
Prashant S. Giri   +2 more
doaj   +1 more source

Startups Driving Artificial Intelligence Into Clinical Dermatology

open access: yesJEADV Clinical Practice, EarlyView.
ABSTRACT Artificial intelligence (AI) is rapidly transitioning from innovation to routine clinical application in dermatology. This review examines how AI‐enabled technologies are being developed and integrated across diverse clinical purposes and workflows.
Dominique Du Crest   +10 more
wiley   +1 more source

Analysis of tumor response and clinical factors associated with vitiligo in patients receiving anti–programmed cell death-1 therapies for melanoma: A cross-sectional studyCapsule Summary

open access: yesJAAD International, 2021
Background: Clinical factors associated with vitiligo in patients receiving anti–programmed cell death-1 (PD-1) remain unknown. Objective: To better characterize the occurrence of vitiligo in patients receiving anti–PD-1.
Léa Dousset, MD   +11 more
doaj   +1 more source

Vitiligo and autoimmune diseases [PDF]

open access: yes, 2016
Vitiligo is a quite frequently occurring skin disease. Although it does not cause any pain or internal organ damage, it constitutes a significant cosmetic problem having a significant impact on quality of life.
Magdalena Kutwin   +2 more
core   +1 more source

Home - About - Disclaimer - Privacy